News articles about Fibrocell (NASDAQ:FCSC) have been trending somewhat positive recently, Accern reports. The research firm identifies negative and positive news coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Fibrocell earned a daily sentiment score of 0.17 on Accern’s scale. Accern also assigned media coverage about the company an impact score of 46.0276568133504 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Here are some of the news headlines that may have effected Accern Sentiment’s rankings:
FCSC has been the subject of a number of research reports. HC Wainwright set a $6.00 price target on shares of Fibrocell and gave the stock a “buy” rating in a research note on Tuesday, January 30th. Zacks Investment Research raised shares of Fibrocell from a “hold” rating to a “buy” rating and set a $0.75 price target for the company in a research note on Tuesday, February 13th. Finally, Griffin Securities reissued a “buy” rating on shares of Fibrocell in a research note on Monday, April 2nd. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $4.58.
Fibrocell traded down $0.16, reaching $0.80, during midday trading on Friday, Marketbeat.com reports. The company had a trading volume of 3,225,261 shares, compared to its average volume of 673,000. Fibrocell has a 1 year low of $0.51 and a 1 year high of $4.64. The stock has a market cap of $27.22 million, a PE ratio of -0.48 and a beta of 0.45.
Fibrocell (NASDAQ:FCSC) last released its quarterly earnings results on Thursday, May 10th. The company reported ($0.11) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.17) by $0.06. sell-side analysts forecast that Fibrocell will post -0.48 earnings per share for the current fiscal year.
Fibrocell Science, Inc, an autologous cell and gene therapy company, focuses on discovering and developing therapies for diseases affecting the skin and connective tissues in the United States. The company's gene therapy product candidates include FCX-007 that is in Phase I/II clinical trials to treat recessive dystrophic epidermolysis bullosa; FCX-013, a gene therapy for localized scleroderma; and gene-therapy program that is in research phase to arthritis and related conditions.
Receive News & Ratings for Fibrocell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fibrocell and related companies with MarketBeat.com's FREE daily email newsletter.